Pediatric Phase I and Pharmacokinetic Study of Erlotinib Followed by the Combination of Erlotinib and Temozolomide: A Children's Oncology Group Phase I Consortium Study

PURPOSE: We conducted a phase I and pharmacokinetic study of the epidermal growth factor receptor (EGFR) inhibitor erlotinib as a single agent and in combination with temozolomide in children with refractory solid tumors. PATIENTS AND METHODS: Erlotinib was administered orally once daily to cohorts...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Jakacki, Regina I., Hamilton, Marta, Gilbertson, Richard J., Blaney, Susan M., Tersak, Jean, Krailo, Mark D., Ingle, Ashish M., Voss, Stephan D., Dancey, Janet E., Adamson, Peter C.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2008
Teme:
Pediatric Oncology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2652086/
https://ncbi.nlm.nih.gov/pubmed/18794549
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2007.15.2306
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items